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Background: Post-menopausal osteoporosis has long been treated and prevented by estrogen replacement
therapy (ERT). Despite its effectiveness, ERT is associated with serious adverse effects. Labisia pumila var. alata (LP) is
a herb with potential as an alternative agent to ERT due to its phytoestrogenic, antioxidative and anti-inflammatory
effects on bone. This study aimed to determine the effects of LP supplementation on bone biomechanical strength
of postmenopausal osteoporosis rat model.
Methods: Ninety-six female Sprague–Dawley rats aged 4 to 5 months old were randomly divided into six groups;
six rats in the baseline group (BL) and eighteen rats in each group of; Sham- operated (Sham), ovariectomised
control (OVXC) and ovariectomised with daily oral gavages of Premarin at 64.5 μg/kg (ERT), LP at 20 mg/kg (LP20) and
LP at 100 mg/kg (LP100) respectively. These groups were subdivided into three, six and nine weeks of treatment
periods. Rats in BL group were euthanized before the start of the study, while other rats were euthanized after
completion of their treatments. Femora were dissected out for biomechanical strength analysis using Instron
Universal Model 5848 Micro Tester.
Results: OVXC group showed deterioration in the bone biomechanical strength with time. Both ERT and LP
supplemented rats showed improvements in bone strength parameters such as maximum load, displacement,
stiffness, stress, and Young Modulus. The most improved bone strength was seen in rats given LP at the dose of
100 mg/kg for nine weeks.
Conclusion: LP supplementation at 100 mg/kg was more effective than ERT in reversing ovariectomy-induced
bone biomechanical changes.
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Osteoporosis is considered as a serious public health
concern due to its increasing prevalence worldwide. It is
a skeletal disease characterized by low bone mass and
microarchitectural deterioration with a consequent in-
crease in bone fragility and susceptibility to fracture [1].
The main types of osteoporotic fractures are hip, wrist
and vertebral fracture. Hip fracture is the most common
form of osteoporotic fractures and is the most serious
complication of osteoporosis. The hip fracture incidence* Correspondence: anazrun@yahoo.com
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article, unless otherwise stated.has been reported to increase worldwide during the last
five decades [2,3]. Women are more susceptible to hip
fractures due to their lower bone density compared to
men. The lifetime risk of hip fracture was 17.5% in
women and 6% in men [4]. The current total number of
women sustaining a hip fracture is estimated to be one
million annually [5] and the total number of hip frac-
tures are expected to surpass 6 million by the year 2050
[6]. Women during the senescence years are mostly
affected due to estrogen deficiency due to menopause or
bilateral ovariectomy. This condition leads to accelerated
bone loss and promotes the development of postmeno-
pausal osteoporosis [7,8].Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Mohd Effendy et al. BMC Complementary and Alternative Medicine  (2015) 15:58 Page 2 of 11Estrogen plays an important role in bone remodelling
via direct effects on estrogen receptors (ERα and ERβ)
located on bone cells. Activation of estrogen-receptor
complex will stimulate osteoblast differentiation and
simultaneously suppress osteoclast activity [9]. The acti-
vation of estrogen-receptor complex will downregulate
Receptor activator of nuclear factor kappa-B ligand
(RANKL), which is crucial for osteoclast formation.
Estrogen will also stimulate the production of an osteo-
clastogenesis inhibitory factor known as osteoprotegrin
(OPG), which will suppress osteoclastic activity. Oppos-
itely, estrogen deficiency will lead to the upregulation of
cytokines such as interleukin-1 (IL-1), IL-6, macrophage
colony-stimulating factor (M-CSF) and tumor necrosis
factor (TNF-α) [10]. These inflammatory cytokines will
induce osteoclast differentiation and inhibit its apop-
tosis. Based on the aforementioned bone protective
effects of estrogen, it is obvious that estrogen deficiency
in postmenopausal women will result in bone loss par-
ticularly cancellous bone on the endosteal surface, which
is an active site for bone growth and remodeling [11,12].
Bone formation activity is unable to keep pace with bone
resorption, resulting in bone loss and fracture risk.
Since estrogen protects against bone loss, its deficiency
in postmenopausal women could be replaced in the form
of estrogen replacement therapy (ERT). In a longitudinal
study of ERT in older postmenopausal women, ERT was
found to increase the bone mineral density at both lum-
bar spine and proximal femur. Histological analysis also
showed an increase in cancellous bone volume and wall
thickness [13]. Estrogen, which can be given alone or in
combination with progesterone exerted antiresorptive
effects on bone cells, affecting the osteoclast activity and
lifespan [14,15]. According to Komm et al. [16], one year
treatment with estrogen in ovariectomised rats were
sufficient to improve the biomechanical properties of
trabecular bone. In another study, administration of
estrogen was able to increase trabecular thickness and
maintain its plate-like trabecular structures, which were
correlated with improved bone strength of ovariecto-
mised mice [17]. However, in human, prolonged use of
ERT may result in long term risks which may outweigh
the benefits. In a large cohort of postmenopausal women
in their 60s, the use of ERT was associated with an
increased risk of breast cancer, coronary heart disease,
stroke and dementia [18-20].
Another form of treatment for postmenopausal osteo-
porosis is selective estrogen-receptor modulators (SERMs)
such as raloxifene and tamoxifen. They are non-steroidal
agents that bind to estrogen receptors, acting as an agonist
on bone but as antagonist to other organs [21]. SERMs
could positively influence the bone mineral density and
strength of the lumbar spine of estrogen-deficient rats
[22]. Raloxifene is the most widely used SERMs forprevention and treatment of osteoporosis. It was re-
ported to prevent bone loss and reduce fracture risk in
postmenopausal women with low bone mass [23,24]. It
has been shown to improve the trabecular bone density
of women with postmenopausal osteoporosis [25]. It
could also improve the structural component of bone
strength [26,27]. Although SERMs are known to reduce
the risks of breast cancer [28], their prolonged use may
result in adverse effects such as thromboembolism,
uterine cancer and cataract [29-31]. Other common
anti-osteoporotic agent is biphosphonates such as alen-
dronate, risedronate and zoledronate. They are potent
inhibitors of bone resorption and effective in the treat-
ment of osteoporosis [32,33]. Their adverse effect
includes abdominal pain, constipation, esophagitis and
osteonecrosis of the mandible [34].
Findings linking estrogen use to several serious dis-
eases have led to many postmenopausal women looking
for other treatment options to prevent and treat post-
menopausal osteoporosis. These alternative treatments
should be effective and with minimal side effects. To
date, some of the natural remedies used for the treat-
ment of osteoporosis includes soy, tocotrienols, Nigella
sativa (black seed), Piper sarmentosum and Labisia
pumila. Labisia pumila (LP) is a traditional herb used
widely by Asian women to treat menstrual irregularities,
painful menstruation, facilitate labour, promote sexual
health function and for post-partum medicine [35,36].
Besides improving women’s health, LP was also reported
to be effective in treating rheumatism and sickness in
the bones [37,38]. There are three known varieties of LP
which are var. pumila, var. alata, and var. lanceolata
[39,40]. In Malaysia, LP is also known by the locals as
Kacip Fatimah, Akar Fatimah, Pokok Pinggang and
Belangkas Hutan [41,42]. It has long been speculated
that LP possesses phytoestrogenic properties, which may
explain its therapeutic values in women’s health. Phy-
toestrogens are naturally-occurring plant compounds
that are structurally and functionally similar to mamma-
lian estrogens and their metabolites [43]. Most phytoes-
trogens such as triterpene and saponins, which are
found in LP, bind to both estrogen receptors ERα and
ERβ, exerting a weaker estrogenic effect compared to
the natural estrogen [44]. Once bound, phytoestrogens
do not act like typical estrogen agonists but rather more
like selective estrogen receptor modulators (SERMs)
[45]. Phytoestrogens in LP could also manipulate steroid
biosynthesis by stimulating sex hormone-binding globu-
lin (SHBG) and displacing estradiol or testosterone [46].
Phytoestrogens are often potent antioxidants and anti-
inflammatory agents which may explain the effects of LP
on women’s health. In a previous study by Nazrun et al.
[47], it was reported that supplementation of LP at the
dose of 17.5 mg/kg was able to increase bone formation
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mized rats. Another study reported an improvement in
the bone structural parameters of LP-supplemented rats
and was able to reverse the osteoporotic changes in
ovariectomized rats [48]. Although LP was proven to
exert an effective effect on bone biochemical and struc-
tural parameters, these results did not truly reflect bone
strength which is an important determinant in the diag-
nosis of osteoporosis and assessment of fracture risk.
The gold standard of assessing risk of osteoporosis has
long been the bone mineral density (BMD) assessment
by dual X-ray absorptiometry (DEXA) [49-51]. Despite
the sensitivity and effectiveness in assessing the risk of
osteoporosis, DEXA does not take into account of bone
strength, the best indicator of fracture risk. Biomechan-
ical test is the gold standard for assessment of bone
strength, which is performed by exerting a load to the
bone until it fractures [52]. In animal models, bone can
be dissected out and its strength tested biomechanically.
However, the human bone strength could only be
assessed indirectly using computer software such as fi-
nite element analysis via micro-computed tomography
(Micro-CT) [53,54].
LP, being a good candidate for ERT alternative, must be
able to exert and sustain its bone strengthening effects with
time. To the best of our knowledge, there is no report of
such parameters on LP. Therefore, this study aimed to de-
termine the time-dependent effects of two LP doses on the
bone strength of postmenopausal osteoporosis rat model.
Methods
Animals and treatment
96 female Sprague–Dawley rats aged 4–5 months weigh-
ing between 200-250 g were obtained from the Univer-
siti Kebangsaan Malaysia Laboratory Animal Research
Unit. The rats were housed in plastic cages at a
temperature of 29 ± 3°C under natural day/night cycle.
They were allowed to adjust to the new environment
for a week before the study was started. They were fed
with commercial food pellets (Gold Coin, Port Klang,
Malaysia) and deionised water ad libitum. They were
then randomly divided into six main groups with six
rats in the baseline group (Baseline) and eighteen rats
in each group of Sham-operated (Sham), ovariecto-
mized control (OVXC), ovariectomized with estrogen
Premarin at 64.5 μg/kg (ERT), ovariectomized with
Labisia pumila at 20 mg/kg (LP20) and ovariectomized
with Labisia pumila at 100 mg/kg (LP100) respectively.
All the treatments were given daily via oral gavages.
These groups were subdivided into three, six and nine
weeks of treatment periods. Body weights were measured
before the start of treatment and weekly until the end of
the study. The study was performed according to the ex-
perimental protocol approved by Universiti KebangsaanMalaysia Animal Ethics Committee (Ethical approval
number: FP/FAR/2011/NAZRUN/30-NOVEMBER/415-
NOVEMBER-2011-MAY-2012).
Labisia pumila var. alata (LP) and Estrogen (ERT)
A raw powdered form of the LP was supplied by Delima
Jelita Herbs (Alor Setar, Kedah). The Labisia pumila var.
alata whole plant was ground and freeze dried into
powdered form. The dried powdered LP extract was sent
to Forest Research Institute Malaysia (FRIM) for phyto-
chemical screening to detect the phytochemical constit-
uents. Based on the phytochemical screening, LP extract
used in this study was found to contain flavonoids, sapo-
nins, tannins, triterpenes and steroids. LP was dissolved in
deionised water and given to the respective groups via oral
gavages at doses of 20 mg/kg and 100 mg/kg rat weight
daily at 9 am for 3, 6 and 9 weeks. Estrogen Premarin®
(Wyeth-Ayerst, Canada) tablet containing 0.625 mg of
conjugated estrogen was crushed, dissolved in deionised
water and given to the respective groups via oral gavages
at the dose of 64.5 μg/kg rat weight daily at 9 am for 3, 6
and 9 weeks.
Bone sampling
Rats in the BL group were euthanized before the start of
the study while the other rats were euthanized upon com-
pletion of their treatments. Femora were dissected and
cleaned from all soft tissues. They were then wrapped in
phosphate-buffered saline-soaked gauze and rewrapped
with aluminium foil prior to storage in −70°C freezer.
These bone samples were allowed to thaw at room
temperature before biomechanically tested. They were also
kept moist at all time during the testing procedure.
Bone biomechanical test
Biomechanical properties of the femoral bones were
assessed using three-point bending test method. This
test was performed using Instron Universal Testing ma-
chine (Model 5848 Microtester, Canton, USA) (Figure 1).
Diameter of each femur was measured and the average
value recorded prior to analysis. The femur was placed
on two holders, one at each end with 5 mm apart. The
holders are perpendicular to the horizontal axis and the
force was applied downward at the specimen midpoint
(Figure 2). Force at a rate of 10 mm/sec was applied to
the midpoint of the femur diaphysis such that the anter-
ior surface was in compression and the posterior surface
in tension until it fractures. The load was increased until
the bone breaks.
Cross-sectional area and shape of the femur were
assumed constant throughout the test. Force and dis-
placement data recorded during the tests were used in
combination with bone geometry parameters to compute
mechanical properties which comprises of both extrinsic
Figure 1 Instron Universal Microtester. Figure 2 Force applied to the midpoint of the femur.
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strain were plotted. The slope of the stress–strain curve
in the elastic region represents Young modulus or
modulus of elasticity. The extrinsic parameters (load,
displacement and stiffness) measure the whole bone
properties, while the intrinsic parameters (stress, strain
and Young modulus) measure the bone material.
Statistical analysis
The data were analysed using Statistical Package for
Social Sciences software (SPSS 19.0, Chicago, USA).
Firstly, the data was tested for normality using the
Kolmogorov-Smirnov test (n = <100). For normally dis-
tributed data, the statistical tests used were the analysis
of variance (ANOVA), followed by Tukey’s HSD test. For
data that was not normally distributed, Kruskal-Wallis and
Mann–Whitney tests were used. All the results were
expressed as mean ± standard error of the mean (SEM).
Results
Maximum load (Max load)
There were gradual increments in the Max load parameter
for the Sham, ERT, LP20 and LP100 groups until they
were significantly higher than the Baseline group at9 weeks. At the same period, the Max load parameter of
the OVX group were significantly lower than the Sham
group. All the treatment groups also showed significantly
higher Max load compared to the OVX group (Figure 3).
Displacement
There was no significant difference in the displacement
value between the Sham and OVX groups. At 6 weeks of
treatment, all the treatment groups showed significantly
higher displacement value than the OVX group at the
corresponding treatment duration. At 9 weeks of treat-
ment, the LP100 group showed a significantly higher
displacement than the ERT group (Figure 4).
Stiffness
An increasing trend in the stiffness value with time can
be seen in all the groups except for the OVX group. At
9 weeks of treatment, the Sham, LP20 and LP100 groups
showed significantly higher stiffness value than the OVX
group (Figure 5).
Stress
An increasing trend in the stress value with time can be
seen in all the groups except for the OVX group. At
Figure 3 Maximum load value for all the groups after 3, 6 and 9 weeks of treatment. Data presented as mean ± SEM (p < 0.05). Sham:
sham-operated, OVX: ovariectomized control, ERT: ovariectomized and estrogen supplementation, LP20: ovariectomized with LP supplementation
(20 mg/kg), LP100: ovariectomized with LP supplementation (100 mg/kg). aP < 0.05 vs Baseline, bP < 0.05 vs Sham at 9 weeks, cP < 0.05 vs OVX of
the corresponding week.
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showed significantly higher stress value than the Baseline
group. At 6 and 9 weeks of treatments, the Sham and all
the treatment groups showed significantly higher stress
value than the OVX group of the corresponding treat-
ment durations. The stress value of the LP100 group
was significantly higher than that of the ERT group
(Figure 6).
Strain
There was an increasing trend in the strain value for all
the treatment groups but no significant difference was
reported (Figure 7).Figure 4 Displacement value for all the groups after 3, 6 and 9 weeks
sham-operated, OVX: ovariectomized control, ERT: ovariectomized and estro
(20 mg/kg), LP100: ovariectomized with LP supplementation (100 mg/kg). a
of treatment.Young modulus
The Young Modulus of the Sham group was significantly
higher than the OVX group at 9 weeks of treatment.
There was a time-dependent increment in the Young
modulus value for the Sham and LP-treated groups. At
9 weeks of treatment, both the LP20 and LP100 groups
showed significantly higher Young modulus than the
Baseline and OVX group (Figure 8).
Discussion
Osteoporosis is one of the most common diseases affecting
1 in 3 women and 1 in 12 men [56]. Worldwide, approxi-
mately 200 million women suffered from osteoporosis andof treatment. Data presented as mean ± SEM (p < 0.05). Sham:
gen supplementation, LP20: ovariectomized with LP supplementation
P < 0.05 vs OVX at 6 weeks of treatment, bP < 0.05 vs ERT at 9 weeks
Figure 5 Stiffness value for all the groups after 3, 6 and 9 weeks of treatment. Data presented as mean ± SEM (p < 0.05). Sham: sham-operated,
OVX: ovariectomized control, ERT: ovariectomized and estrogen supplementation, LP20: ovariectomized with LP supplementation (20 mg/kg), LP100:
ovariectomized with LP supplementation (100 mg/kg). aP < 0.05 vs OVX.
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nearly 40% [57]. Although effective treatments are available
for osteoporosis, their prolonged use was associated with
adverse effects such as breast cancer, thromboembolic and
coronary heart disease. This has led to an increase in the
demand for alternative medicine to treat and prevent
osteoporosis. It has also attracted studies to search for po-
tential agents to replace ERT. In recent years, a medicinal
plant known as Labisia pumila (LP) was reported to pos-
sess anti-osteoporosis activities. It was reported that LP
was able to increase bone formation and reduce the bone
resorption markers in ovariectomized rats [47]. LP supple-
mentation was also shown to protect the bone structure
changes of estrogen-deficient rats [48].
In a previous study, the authors have investigated the
time-dependent effects of two doses of LP (20 mg a/kgFigure 6 Stress value for all groups at 3, 6 and 9 weeks of treatment.
ovariectomized control, ERT: ovariectomized and estrogen supplementation
ovariectomized with LP supplementation (100 mg/kg). aP < 0.05 vs Baselineand 100 mg/kg) using in vitro micro-CT. Supplementa-
tion of LP 100 mg/kg for 9 weeks showed the best effect
in reversing the ovariectomy-induced bone changes.
Bone structural parameters such as bone volume frac-
tion, connectivity density and trabecular number were
increased and trabecular separation decreased signifi-
cantly in OVX rats treated with LP100 for 9 weeks.
Three dimensional (3D) analysis also showed that the
trabecular microarchitecture of LP treated rats improved
significantly compared to other groups [58]. Following
these positive results of LP on bone microarchitecture,
our present study was performed to evaluate further the
effects of LP on bone strength.
The diagnosis of osteoporosis is often based on bone
density. However, a denser bone does not always mean
stronger bone as in the case of fluoride treatment ofData presented as mean ± SEM (p < 0.05). Sham: sham-operated, OVX:
, LP20: ovariectomized with LP supplementation (20 mg/kg), LP100:
, bP < 0.05 vs OVX, cP < 0.05 vs ERT.
Figure 7 Strain value for all the groups at 3, 6 and 9 weeks of treatment. Data presented as mean ± SEM (p < 0.05). Sham: sham-operated,
OVX: ovariectomized control, ERT: ovariectomized and estrogen supplementation, LP20: ovariectomized with LP supplementation (20 mg/kg),
LP100: ovariectomized with LP supplementation (100 mg/kg).
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though it appeared to be dense [59,60]. Hence, it is im-
portant to study the bone mass, structure and strength
as a whole to determine bone quality. Bone markers and
histomorphometry parameters alone are not strong indi-
cators of bone quality. It is the bone strength which
plays a vital role in predicting early fracture risk [61,62].
The term bone quality refers to all characteristics be-
yond bone mass that influence the ability of bone to
bear loads [63]. In accordance with this, bone biomech-
anics should be measured to study its strength. Bone
strength analysis may also provide information on the
effects of different treatments on bone.Figure 8 Young modulus value for all groups after 3, 6 and 9 weeks o
sham-operated, OVX: ovariectomized control, ERT: ovariectomized and estro
at the dose of 20 mg/kg, LP100: ovariectomized with LP supplementationEstrogen deficiency following ovariectomy resulted in
tremendous bone loss with bone resorption activity out-
weighing bone formation activity [64,65]. These bone
changes have led to profound reductions in bone density
and bone mechanical strength [66]. The trabecular
thinning and reduction of horizontal trabeculae resulted
in significant reduction in bone stiffness [67,68]. This is
in line with Kennedy et al. [69] which reported that
ovariectomised rats had reduced stiffness and yield
strength. Estrogen maintained bone strength by pro-
moting osteoblast differentiation [70-72] and stimu-
lating the production of osteoprotegrin (OPG), a potent
anti-osteoclastogenic factor [73,74]. Estrogen may alsof treatment. Data presented as mean ± SEM (p < 0.05). Sham:
gen supplementation, LP20: ovariectomized with LP supplementation
at the dose of 100 mg/kg. aP < 0.05 vs baseline, bP < 0.05 vs OVX.
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ing the oxidative stress-induced bone loss [75].
In this study, two doses of LP were given to ovariecto-
mized rats for three different time intervals; 3, 6 and
9 weeks to evaluate the dose and time-dependent effects
of LP on bone biomechanical strength. The 20 mg/kg
dose was a round up value of the 17.5 mg/kg standard
dose used in a previous study [47,48]. While, the higher
dose was set at five times higher to 100 mg/kg. Ideally,
several doses of LP should have been tested, but due to
ethical reasons, this was not possible as we are required to
reduce the number of animals used in the study. Accord-
ing to previous toxicity studies, LP extract was shown to
be safe with the lethal dose 50 (LD50) of more than
5.0 g/kg [76]. In other studies, LP extract was shown to
exhibit no-adverse-effect-level (NOAEL) at the dose of
50 mg/kg in a sub-acute study [77], 1000 mg/kg in a
sub-chronic study [78] and 800 mg/kg in reproductive
toxicity testing. Therefore, the doses of 20 mg/kg and
100 mg/kg used in the study were safe. In humans, LP is
normally taken by women in the dose of 500 to
1000 mg/daily.
Whole bone biomechanical tests can be performed in
bending, tension, compression and torsional loading set-
tings [79]. Bending is most commonly applied to ro-
dents’ long bones due to difficulties of machining tensile
or compressive specimens from small bones. There are
two types of parameters which can be derived from a
biomechanical test; the extrinsic and intrinsic parame-
ters. Extrinsic parameters reflect the properties of whole
bone which are affected by various external factors. They
comprise of load, displacement and stiffness. Intrinsic
parameters on the other hand reflect the inner material
of bones such as its geometric distribution and cellular
metabolic activity affecting the bone’s ability to bear
loads. Intrinsic parameters comprise of stress, strain and
modulus of elasticity.
In this study, the bone of rats supplemented with LP
showed significant improvement in both the extrinsic
and intrinsic parameters. As expected, the OVX group
showed deterioration in the biomechanical strength pa-
rameters and by the ninth-week of treatment most of
these parameters were significantly lower than the Sham
group. This finding was supported by previous studies
which reported that ovariectomized rats showed signifi-
cant deteriorations in the bone structure in the first
three months [80]. Another study reported that there
was no sign of bone changes in less than one month
after ovariectomy. This is consistent with our findings
that there was no significant change in bone strength
parameters at 3 weeks post-ovariectomy.
Maximum or ultimate load indicates the whole bone
strength at the point where the femur started to change
from elastic to plastic phase. Maximum load can bedefined as the maximum amount of force needed to
break the bone. It reflects the general integrity of the
bone structure. The bones of all the treatment groups
showed gradual increments in the maximum load until
they were significantly higher compared to the Baseline
and OVX groups at nine weeks post-ovariectomy. Both
doses of LP supplementations improved bone strength
and were comparable to ERT in withstanding the given
load. Displacement is another extrinsic parameter which
is defined as the length of deformation that the bone
can sustain before failing [81]. It can be used to measure
bone ductility and is inversely related to the brittleness
of the bone [82]. Rats supplemented with 100 mg/kg dose
of LP for the duration of nine weeks had the most ductile
bones compared to others. Their bones were also having
significantly higher displacement values compared to the
ERT group. These results showed that although both the
ERT and LP100 groups had strong bones in terms of sus-
taining high amount of load, the bones of LP100 were
more ductile and hence harder to break.
The load - displacement curve may give a clearer un-
derstanding of bone strength. The linear region of this
curve represents the elastic property of a bone, where
the deformation upon loading is reversible [83]. The gra-
dient under this elastic region depicts the extrinsic stiff-
ness or rigidity. It represents bone mineralization of the
relative hydroxyapatite and collagen fibers proportion
[84,85]. Beyond the point of yielding is the plastic region,
where permanent deformation occurs upon compressive
force. In this study, the Sham, LP20 and LP100 groups
showed significantly higher bone stiffness at 9 weeks
post-treatment compared to the OVX group. The infer-
ior bone stiffness of the OVX group was expected as
many studies have reported that ovariectomy affected
not only the bone mass but the bone quality as well
[86,87]. Surprisingly, LP supplementation was able to
improve the bone stiffness of ovariectomised rats while
ERT failed to do so.
Bone biomechanical testing is not only focused on the
mechanical behaviour of the whole bone but also the
mechanical properties at tissue level or intrinsic proper-
ties. Intrinsic parameters measured were stress, strain
and Young’s modulus. Stress is the strength of the bone
tissue under a given loading condition. In this study, the
Sham and all the treatment groups were able to receive
higher stress compared to the OVX group after 6 and
9 weeks of treatment. The LP100 group was able to
receive the greatest stress at 9 weeks, which was signifi-
cantly higher than the ERT group. This indicated that
the bone tissue of the LP100 group was able to absorb
higher energy before failure than the ERT group. As for
the Strain parameter, it represents ductility of the bone
[88,89]. However, there were no significant changes in
this parameter for all the groups.
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modulus of elasticity which is also known as Young’s
modulus. Young’s modulus is influenced by the amount
of collagen and calcification process in the bone. After
9 weeks of treatment, the Sham, LP20 and LP100 groups
had significantly higher bone elasticity than the OVX
group. This indicated that the bones of the Sham and LP
groups were much more elastic than the OVX group
and less likely to fracture. Based on all the results, sup-
plementation of LP at 100 mg/kg were able to preserve
bone strength from the deleterious effects of ovariec-
tomy. At this dose, LP was found to be better than ERT
in maintaining bone strength and ductility.
There are several possible mechanisms behind the
ability of LP to retain bone strength during estrogen defi-
ciency state. LP extract contains triterpenes and saponins,
which are known phytoestrogens [90]. Phytoestrogen can
mimic or modulate the action of endogenous estrogens by
binding to estrogen receptors [91,92]. It was reported that
phytoestrogen exerted bone sparing effects in a rat model
[93,94]. Similar to estrogen, LP through its phytoestogenic
activity may induce and inhibit osteoclasts and osteoblast
apoptosis respectively. Therefore, LP may maintain bone
strength by reducing bone resorption and increasing bone
formation activities [95].
Besides the phytoestrogenic property, LP may exert
anti-oxidative effects on the bone. According to Norhaiza
et al. [96], the anti-oxidative property of LP was con-
tributed by its content of flavonoids, ascorbic acids, beta-
carotene, anthocyanin and phenolic compounds. Estrogen
deficiency leads to deterioration in anti-oxidant defense
system and upregulation of reactive oxygen species (ROS).
These imbalances resulted in lipid peroxidation and bone
loss [97]. Hence, supplementation of LP may abate oxida-
tive stress, thus preventing bone loss and maintaining
bone strength.
There are some raised concerns on the risk of endo-
metrial hyperplasia and excessive cell growth in the
uterus, secondary to the use of phytoestrogens. However,
many previous studies had shown that LP exhibits anti-
proliferative effects [98]. A polar solvent extract such as
LP water extract had been shown to reduce risks of cell
proliferation. The bioactive compounds that are respon-
sible for estrogenic activity are more polar in nature,
hence they are highly expressed in water extract. This is
in contrast to a less polar solvent extracts such as ethanol
and dichloromethane LP extracts which may induce an in-
crease in cell proliferation [99]. Hence, LP water extract
used in this study may exhibit an estrogenic effect without
the risk of excessive cell proliferation. This is also sup-
ported by previous toxicity studies which reported that LP
extract did not alter the rats’ general health and no gross
visceral changes of the ovaries or uterus were found at the
dose up to 800 mg/kg/day [76,77]. Although LP is safeand effective, further studies are warranted to document a
conclusive mechanisms of its therapeutic action.
Conclusions
As a conclusion, LP supplementation at the dose of
100 mg/kg for 9 weeks duration of treatment was found
to be more effective than ERT in maintaining the bone
strength of a postmenopausal osteoporosis rat model.
Based on its safety profile and ability to preserve bone
strength, LP has potential as an alternative treatment for
postmenopausal osteoporosis.
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